AZD8797
(Synonyms: KAND567) 目录号 : GC31653
AZD8797是一种选择性高亲和力CX3CR1小分子抑制剂，对大鼠CX3CR1的Ki值为7nM。
Cas No.:911715-90-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
AZD8797 is a selective, high-affinity small-molecule inhibitor of CX3CR1, with a Ki value of 7nM for rat CX3CR1 [1]. AZD8797 has been widely used to inhibit inflammatory responses in different animal models by binding to receptors at different sites of CX3CL1 to affect CX3CL1 interaction with CX3CR1[2].
In vitro, AZD8797 pretreatment (2mM) for 1 hour significantly decreased the expression levels of CX3CR1 and MMP13 in rat chondrocytes after 24h lipopolysaccharide (LPS) stimulation[3]. Co-treatment of 5μM AZD8797 with 5μM olaparib for 48 hours significantly inhibited Caov-3 cell colony formation and inhibited cell proliferation[4]. Treatment with 10μM AZD8797 for 12 hours resulted in down-regulation of 5-HTR2a expression and decreased phosphorylation of P65 and IκB proteins in PC-12 cells[5].
In vivo, AZD8797 treatment via intraperitoneal injection at a dose of 10mg/kg/day for 10 days reduced spleen mass and cardiac levels of CCL2 and IL-15, with an increase of IL-4 in the mice with acute Trypanosoma cruzi infection[6]. Daily intraperitoneal injection of AZD8797 at a dose of 80μg/kg/day for 10 days can enhance the early behavioral recovery, inhibit the activation of apoptosis, and reduce the inflammatory response in a rat spinal cord injury model[7]. AZD8797 (2mg/kg/day) administered via the tail vein for 5 days reduced proteinuria, cell proliferation, and inflammation of glomerulus in rats with mesangial proliferative glomerulonephritis (MsPGN)[8].
References:
[1] Ridderstad Wollberg A, Ericsson-Dahlstrand A, Juréus A, et al. Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis[J]. Proceedings of the National Academy of Sciences, 2014, 111(14): 5409-5414.
[2] Huang J M, Zhao N, Hao X N, et al. CX3CL1/CX3CR1 signaling mediated neuroglia activation is implicated in the retinal degeneration: a potential therapeutic target to prevent photoreceptor death[J]. Investigative Ophthalmology & Visual Science, 2024, 65(1): 29-29.
[3] Huang J, Zheng X, Meng J, et al. Experimental study on the role and biomarker potential of CX3CR1 in osteoarthritis[J]. Annals of medicine, 2025, 57(1): 2529577.
[4] Xie J, Barbolina M V. Dual Targeting of CX3CR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma[J]. Cancers, 2024, 16(22): 3728.
[5] Pei J, Zou Y, Wan C, et al. CX3CR1 mediates motor dysfunction in mice through 5-HTR2a[J]. Behavioural brain research, 2024, 461: 114837.
[6] Pio S, Menezes T P, Louise V, et al. Role of the CX3CL1/CX3CR1 axis in iron metabolism and immune regulation during acute Trypanosoma cruzi infection[J]. Frontiers in Immunology, 2025, 16: 1585883.
[7] Chen G, Zhou Z, Sha W, et al. A novel CX3CR1 inhibitor AZD8797 facilitates early recovery of rat acute spinal cord injury by inhibiting inflammation and apoptosis[J]. International journal of molecular medicine, 2020, 45(5): 1373-1384.
[8] Zhang J, Fang Q, Huang Y, et al. CX3CR1+ Monocytes/Macrophages Promote Regional Immune Injury in Mesangial Proliferative Glomerulonephritis through Crosstalk with Activated Mesangial Cells[J]. Research, 2025, 8: 0716.
AZD8797是一种选择性高亲和力CX3CR1小分子抑制剂，对大鼠CX3CR1的Ki值为7nM[1]。AZD8797通过在不同位点与受体结合影响CX3CL1与CX3CR1的相互作用，已广泛应用于不同动物模型中抑制炎症反应[2]。
在体外，2mM的AZD8797预处理1小时可显著降低脂多糖（LPS）刺激24小时后大鼠软骨细胞中CX3CR1和MMP13的表达水平[3]。5μM的AZD8797与5μM奥拉帕利联合处理48小时能显著抑制Caov-3细胞集落形成和增殖[4]。10μM的AZD8797处理PC-12细胞12小时可下调5-HTR2a表达，并降低P65和IκB蛋白的磷酸化水平[5]。
在体内，急性克氏锥虫感染小鼠每日腹腔注射AZD8797（10mg/kg/day；持续10天）可减轻脾脏质量，降低心脏CCL2和IL-15水平，并增加IL-4[6]。脊髓损伤大鼠模型每日腹腔注射80μg/kg/day剂量的AZD8797（持续10天）能促进早期行为恢复，抑制细胞凋亡激活并减轻炎症反应[7]。系膜增生性肾小球肾炎（MsPGN）大鼠经尾静脉注射AZD8797（2mg/kg/day；持续5天）可减少蛋白尿、细胞增殖和肾小球炎症[8]。
| Cell experiment [1]: | |
Cell lines | Rat chondrocytes |
Preparation Method | Rat chondrocytes were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C in 5% CO2. The third passage of chondrocytes was used for subsequent experiments. An in vitro OA model was established by exposing chondrocytes to 1mg/ml lipopolysaccharide (LPS) for 24 hours. The experimental conditions were divided into three groups: (1) untreated control group; (2) OA group, LPS stimulation (1mg/ml); (3) OA+AZD8797 group, preincubated with 2mM AZD8797 for 1 hour before LPS treatment. After that, qRT-PCR and immunoblot analysis were performed. |
Reaction Conditions | 2mM; 1h |
Applications | AZD8797 treatment significantly decreased the expression levels of CX3CR1 and MMP13 in chondrocytes after LPS stimulation. |
| Animal experiment [2]: | |
Animal models | Male Wistar rats |
Preparation Method | Male Wistar rats (6-8 weeks old, 200-250g) were maintained under constant temperature (20°C), constant humidity (70%), and alternating day and night. The MsPGN model was established by injecting anti-Thy1 antibody (2.5mg/kg) through the tail vein, and the control group was injected with the same volume of normal saline. AZD8797 (2mg/kg/day) was injected daily through the tail vein from day 3 to day 7 after the model establishment. On days 7, 10, and 14 after modeling, the rats were sacrificed after pentobarbital anesthesia, and blood, urine, and kidney tissue were collected for analysis. |
Dosage form | 2mg/kg/day for 5 days; tail vein injection |
Applications | AZD8797 treatment ameliorated proteinuria, cell proliferation, and inflammation of the glomerulus in the rats. |
References: | |
| Cas No. | 911715-90-7 | SDF | |
| 别名 | KAND567 | ||
| Canonical SMILES | CC(C)C[C@@H](NC1=NC(S[C@@H](C)C2=CC=CC=C2)=NC3=C1SC(N)=N3)CO | ||
| 分子式 | C19H25N5OS2 | 分子量 | 403.56 |
| 溶解度 | DMSO : ≥ 150 mg/mL (371.69 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4779 mL | 12.3897 mL | 24.7795 mL |
| 5 mM | 495.6 μL | 2.4779 mL | 4.9559 mL |
| 10 mM | 247.8 μL | 1.239 mL | 2.4779 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet